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OBJECTIVE — Toassessiftoothdiscolorationisanovelsideeffectofsulfonylureatherapyin
patients with permanent neonatal diabetes due to mutations in KCNJ11.
RESEARCH DESIGN AND METHODS — A total of 67 patients with a known KCNJ11
mutation who had been successfully transferred from insulin injections onto oral sulfonylureas
were contacted and asked about the development of tooth discoloration after transfer.
RESULTS — Alteredtoothappearancewasidentiﬁedin5ofthe67patients.Thiswasvariable
in severity, ranging from mild discoloration/staining (n  4) to loss of enamel (n  1) and was
only seen in patients taking glibenclamide (glyburide).
CONCLUSIONS — These previously unreported side effects may relate to the developing
tooth and/or to the high local concentrations in the children who frequently chewed gliben-
clamide tablets or took it as a concentrated solution. Given the multiple beneﬁts of sulfonylurea
treatment for patients with activating KCNJ11 mutations, this association warrants further in-
vestigation but should not preclude such treatment.
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A
ctivating mutations in KCNJ11,
which encodes the Kir6.2 subunit
of the ATP-sensitive potassium
(KATP) channel, are the most common
known cause of permanent neonatal di-
abetes (1,2). High-dose glibenclamide
(glyburide) allows discontinuation of
insulin and improves metabolic control
in 90% of cases (2,3). Apart from
transient diarrhea (4), no signiﬁcant
side effects have been reported. We re-
port the development of tooth discolor-
ation in ﬁve patients with a KCNJ11
mutation after successful transfer onto
glibenclamide.
RESEARCH DESIGN AND
METHODS— This study was con-
ducted in accordance with the Declara-
tion of Helsinki. Informed consent was
obtained from all patients or their legal
guardians.
Genetic testing was performed at the
Peninsula Medical School, Exeter, U.K.,
or the University of Chicago, IL, as previ-
ously described (1,2). After an observa-
tion by the authors of patient 1 (see
below), the association between sulfonyl-
urea treatment and tooth discoloration
wasfurtherinvestigatedbycontactingthe
referring clinicians of another 66 patients
with neonatal diabetes resulting from a
KCNJ11 mutation that had successfully
transferred onto sulfonylureas.
RESULTS— Tooth discoloration was
identiﬁed in ﬁve patients, representing
7.5% of the 67 subjects with a KCNJ11
mutationtreatedwithsulfonylureasinthe
two centers. These subjects and their ge-
notypes have previously been reported
(1–3).Asummaryoftheirclinicalcharac-
teristics is provided in Table 1.
Discoloration of the permanent teeth
(markedly the incisors) was noted in pa-
tient16m onths after transfer, while on
high-dose glibenclamide. She used to
chew the tablets. Although glibenclamide
dose was decreased to 0.6 mg   kg
1  
day
1 without deterioration in metabolic
control and the patient stopped chewing
the pills, there has been no improvement
in her teeth color. Patient 2 developed
loss of enamel in the upper molars and
discolorationofdeciduousincisorsover4
years after transfer onto a glibenclamide
syrup (2.5 mg/ml). Interestingly, no dis-
coloration of the recently erupted perma-
nent teeth has been noted. In patient 3, a
yellowish discoloration of the deciduous
teeth was noted 1 month after transfer,
during which time the tablets were being
crushed and placed in liquid or food. A
couple of months later, she began par-
tially chewing or swallowing the tablets
whole. The discoloration resolved since
and has not recurred. Patient 4, who was
swallowing her pills, was noted about 3
monthsaftertransfertohaveaplaque-like
yellowish discoloration affecting primar-
ily the front teeth. The discoloration was
easily removed by routine cleaning every
3–4 months. Patient 5 was initially dis-
solving the pills in liquid, but around the
time he began chewing the pills, he was
notedtohaveinconsistentgrayishdiscolor-
ing of his deciduous teeth. This discolora-
tion was much improved after thorough
brushingoftheteeth.Noneofthepatients
reported recent changes in food intake,
druguseotherthanglibenclamide,family
history, or any other known risk factors
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the association.
CONCLUSIONS — We describe ﬁve
patients with a KCNJ11 mutation devel-
oping tooth discoloration 1–55 months
after transfer from insulin onto gliben-
clamide. The severity of this novel side
effect varied from easily removable tooth
staining to nonreversible discoloration
and loss of enamel.
Tooth discoloration has not previ-
ously been described despite widespread
use of glibenclamide in adults. There are
manypossibleexplanationsforthis.First,
our patients are much younger than pa-
tients with type 2 diabetes, and tooth dis-
coloration is more noticeable in white
deciduous than in the permanent teeth,
which tend to be darker. Second, the
doses used in children are usually higher
than the maximum doses used in adults
(3). However, there seems to be no clear
relationship between glibenclamide dose
and the development of tooth discolora-
tionwithinourcohort,sincepatient2was
onalowdose(0.1mg kg
1 day
1),and
no tooth discoloration was noted in a fur-
ther 62 patients with KCNJ11 diabetes
who were successfully managed on simi-
lar doses of sulfonylureas. Third, and
most likely, the teeth may have been ex-
posedtohighlocalconcentrationsofglib-
enclamide because of tablets being
chewed or taken in solution. In keeping
withthis,mostevidenceindicatesthatthe
causeoftoothstainingistheprecipitation
of ingested chromogens onto dental sur-
face (5). However, the possible patho-
genic mechanism for the more severe
effectonenamelseeninpatient2remains
unclear. Many other pediatric liquid medi-
caments have an erosive effect on the pri-
mary enamel surface (6). In addition to this
local effect, it may relate to a decrease in
bloodﬂowtotheteeth,sinceglibenclamide,
a nonselective sulfonylurea, reduces blood
ﬂowtothedentalpulpby70%(7)byacting
on vascular KATP channels (composed of
Kir6.1andSUR2B)(8).Itmightalsobepos-
sible that loss of enamel is unrelated to sul-
fonylurea therapy, since it was present in
deciduousteethbutnotinpermanentteeth.
Clinicians should be aware of this
novel side effect of glibenclamide therapy
in patients with neonatal diabetes result-
ing from a KCNJ11 mutation. While the
cause is uncertain, patients should prob-
ably be advised not to chew tablets. Al-
though the effect seems to have mainly a
cosmetic consequence and should thus
not preclude such treatment, this previ-
ously unreported association warrants
further investigation.
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